QUINAZOLIN-4-YL-PIPERIDINE AND CINNOLIN-4-YL-PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS
申请人:Pfizer Products Incorporated
公开号:EP1773805A1
公开(公告)日:2007-04-18
US7268142B2
申请人:——
公开号:US7268142B2
公开(公告)日:2007-09-11
[EN] TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE<br/>[FR] DERIVES TETRAHYDROISOQUINOLINYLIQUES DE QUINAZOLINE ET D'ISOQUINOLINE
申请人:PFIZER PROD INC
公开号:WO2005082883A2
公开(公告)日:2005-09-09
The invention pertains to substituted quinazoline and isoquinoline of formula (I) that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE-10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders. or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[EN] QUINAZOLIN-4-YL- PIPERIDINE AND CINNOLIN-4-YL- PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DERIVES QUINAZOLIN-4-YL- PIPERIDINE ET CINNOLIN-4-YL-PIPERIDINE UTILISES EN TANT QU'INHIBITEURS DE PDE10 POUR LE TRAITEMENT DE TROUBLES DU SNC
申请人:PFIZER PROD INC
公开号:WO2006011040A1
公开(公告)日:2006-02-02
The invention pertains to new piperidyl-substituted quinazoline and isoquínoline derivatives of formula (I) that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders.
Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
申请人:Allen Patrick Martin
公开号:US20050182079A1
公开(公告)日:2005-08-18
The invention pertains to substituted quinazoline and isoquinoline compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE-10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.